Mouwasat

Healthcare: Healthcare Provider MOUWASAT AB: Saudi Arabia

24 April 2024



US\$7.3bn 47.47% US\$13.2mn
Market Cap. Free Float Avg. Daily Value traded

Research Department **Madhu Appissa, CFA**Tel +966 11 836 5464, appissam@alrajhi-capital.com

Neutral

Price Target (SAR): 138.0

Current: 137.0

Upside/Downside: 0.7% above current

Valuation Multiples	23	24E	25E
P/E (x)	41.7	34.2	31.3
P/B (x)	8.7	7.8	7.0
ROE (%)	20.2	22.1	21.6

Major Shareholders % Ownership

Al Subaie Mohammed Sultan Hammed	17.5
Al Subaie Nasser Sultan Fahad	17.5
Al-Saleem Suleiman Muhammad Suleiman	17.5

Price Performance	1M	3M	YTD
Absolute	11.6%	13.2%	22.5%
Relative to TASI	14.3%	10.1%	18.2%

Earnings

(SARmn)	2023	2024E	2025E
Revenue	2,706	3,103	3,505
Revenue growth	16%	15%	13%
Gross profit	1,313	1,492	1,641
Gross margin	49%	48%	47%
Operating profit	748	910	990
Op. margins	28%	29%	28%
Net profit	658	801	875
Net margin	24%	26%	25%
EPS	3.29	4.01	4.38
DPS	1.75	2.13	2.33
Payout ratio	53%	53%	53%
P/E	41.7x	34.2x	31.3x
RoE	20.2%	22.1%	21.6%

Source: Company data, Al Rajhi Capital

Mouwasat

Price hikes to offset cost pressure

Despite Q4 being a moderate quarter in terms of seasonality in 2023 for most operators, Mouwasat reported solid topline growth in Q4 2023 and outgrew its Riyadh-based peers. We noticed that the Riyadh based operators (ex-Saudi German) faced some weakness in Q4 in terms of seasonal impact as the sequential growth was only 3%, however, for Mouwasat the sequential growth in topline was 21%. In our view, this could be due to its higher presence in the eastern region, that has relatively more expats, while the Riyadh based operators are more geared towards local. Thus, the seasonality pattern is different for Mouwasat and its peers. To put things into perspective, sequential growth in Q3 for Mouwasat was just 2%, while for its Riyadh-based peers it was 9%. Additionally, in Q4 for Mouwasat, there could have been positive impact from change in terms for Aramco patients, from per capita to fee for service. As per the company, the company was expecting positive benefit of 10% improvement in revenues per patient starting November 2023. At the moment, we do not have clarity on the pricing improvement in Q4 2023. Thus, we would be cautious to extrapolate Q4 earnings for entire 2024. In our view, Q1 2024 earnings could be sequentially down despite improvement in pricing for insurance clientele and opening up of Madina LTC facility. We estimate Q1 revenue to decline by almost 2% Q-o-Q to SAR 761 mn, but profits to improve as we consider normalized ECL provisions in Q1 (Q4 2023 operating expenses shot up on ECL provisions).

Nevertheless, 2024 as a whole is expected to witness mid-teens topline growth for the company led by price revisions from insurance and contribution from LTC facility at Madina (opened in Q1 2024) and ramp up of Dammam. We see upside risks to our revenue estimates for 2024 once we have more clarity on the impact of change in terms for John Hopkins contract, currently we are not considering any positive impact. On gross margins, we estimate some contraction related to pre-operating costs for LTC facility in Madina and ramp up at Dammam. However, we expect normalized ECL provisions in 2024 to support operating margins. Overall, we estimate net income to grow by 22% supported by better operating margins.

Post the recent rally, the stock trades at a 2024E P/E of 34x and at 31x on 2025E EPS estimates. In our view, the stock is fairly valued at the current level. Post the beat in Q4 numbers on topline and expectations of improvement in net income in Q1 supported by normalized ECL provisions, we raise our target price to SAR 138/share from SAR 128/share before, but maintain neutral recommendation on the stock. Our fair value is derived through target P/E of 33x on average EPS of 2024 and 2025 (details below).

Figure 1 Summary of Q1 Estimates

(SARmn)	1Q24E	4Q23	3Q23	2Q23	1Q23	1Q24E y-o-y	1Q24E q-o-q
Revenue	761	773	641	627	664	15%	-2%
Gross Profit	376	395	298	292	328	14%	-5%
Gross Margin	49%	51%	47%	47%	49%		
Operating Profit	239	202	182	172	193	24%	18%
Operating Margin	31%	26%	28%	27%	29%		
Net Income	214	184	156	151	167	28%	16%
Net Income Margin	28%	24%	24%	24%	25%		

Source: Company Data, Al Rajhi Capital Estimates


Healthcare: Healthcare Provider MOUWASAT AB: Saudi Arabia

24 April 2024



Valuations: Based on the above-mentioned catalysts (price hikes from insurance and capacity increase), we estimate the topline to grow by 15% and 13% in 2024 and 2025, respectively. We assign a P/E multiple of 33x to 2024/2025E EPS and arrive at our new target price of SAR 138/share, offering around 1% upside from the current levels and implying Neutral recommendation on the stock. The key upside risks to our assumptions are price hikes from insurance, no negative impact from change in terms of Aramco contract, etc.

Figure 2 Mouwasat vs Healhtcare Index (Rebased to Figure 3 Valuations 100)



Relative Valuation	Multiples
Forward P/E	33.0x
2024E/2025E EPS	4.19
Value per share	138.0
CMP	137.0
Upside/Downside	0.7%

Source: Bloomberg, Al Rajhi Capital

Source: Company Data, Al Rajhi Capital

24 April 2024



Financials

Figure 4 Income Statement

(SARmn)	2023	2024E	2025E
Revenue	2,706	3,103	3,505
Y/Y%	16%	15%	13%
COGS	(1,392)	(1,610)	(1,864)
Gross profit	1,313	1,492	1,641
Y/Y%	19%	14%	10%
Gross margin	49%	48%	47%
Operating Expenses	(448)	(522)	(593)
ECL	(117)	(60)	(63)
Operating profit	748	910	985
Op. margins	28%	29%	28%
Investments and other	25	20	25
Financing Expense	(46)	(52)	(56)
Profit before tax	727	878	954
Zakat & Tax	(39)	(44)	(48)
Minority Interest	(31)	(33)	(36)
Net profit	658	801	870
Net margin	24%	26%	25%
EPS	3.29	4.01	4.35

Source: Al Rajhi Capital estimates

Figure 6 Cash Flow Statement

(SARmn)	2023	2024E	2025E
Cash Flows from Operating Activities	814	898	1,054
Cash Flows from Investing Activities	(475)	(494)	(796)
Cash Flows from Financing Activities	(434)	(300)	(184)
Change in Cash	(95)	104	75
Cash & Cash Equivalents at End of year	49	153	228

Source: Al Rajhi Capital estimates

Figure 5 Balance sheet

(SARmn)	2023	2024E	2025E
Cash & Cash Equivalents	49	153	228
Receivables, Net	1,154	1,334	1,472
Inventory	197	247	311
Other	218	218	218
Total Current Assets	1,618	1,953	2,229
Fixed Assets	3,046	3,295	3,806
Other	244	255	265
Right-of-use asset	20	20	20
Intangibles	37	37	37
Total Non-current Assets	3,347	3,606	4,127
Assets	4,965	5,558	6,356
Trade payable	232	291	366
Others	329	329	329
Short-term Debt	266	106	0
Short-term lease liabilities	4	4	4
Total Current Liabilities	831	730	698
Long-Term Debt	500	787	1,172
Long-term lease liabilities	19	19	19
Other	188	188	188
Total Non-current Liabilities	707	994	1,379
Total Owners Equity	3,427	3,835	4,278
Total Liabilities	4,965	5,558	6,356

Source: Al Rajhi Capital estimates

Mouwasat

Healthcare: Healthcare Provider MOUWASAT AB: Saudi Arabia

24 April 2024



IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi (Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Raihi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Raihi,

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Mouwasat

Healthcare: Healthcare Provider MOUWASAT AB: Saudi Arabia

24 April 2024



Disclaimer and additional disclosures for Equity Research

Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

Contact us

Mazen AlSudairi, CFA, CMT Head of Research

Tel: +966 11 836 5468

Email: alsudairim@alrajhi-capital.com

Al Rajhi Capital

Research Department Head Office, King Fahad Road P.O. Box 5561, Riyadh 11432 Kingdom of Saudi Arabia

Email: research@alrajhi-capital.com

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37